This phase II trial is trying to understand whether the addition of a new drug (avatrombopag) to standard immunosuppressive therapy (IST) can effectively treat patients with severe aplastic anaemia who have not had prior treatment.
This trial is treating patients with severe aplastic anaemia.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) – a Bayesian Optimal Phase II study
Other Non-Commercial Sponsor
Eligible patients will receive oral Avatrombopag at a maximum dose of 60 mg per day for up to 180 days. The Avatrombopag dose will be adjusted every 2 weeks guided by reticulocyte count, platelet count/platelet transfusion and neutrophil count.
Recruiting Hospitals Read More